409A Valuation for an Outpatient Physical Therapy Network

Medicare and commercial payer rate changes for outpatient therapy are often known well in advance of taking effect, and a 409A that projects forward revenue using current reimbursement rates, without adjusting for an already-announced cut, is building on an assumption that won't hold for long. If a rate change affecting a meaningful share of your visit volume is scheduled, whether it's a Medicare fee schedule adjustment or a commercial payer contract renegotiation, tell your appraiser the specifics rather than letting them extrapolate off last year's numbers.

The same logic applies to a rate increase. If you've recently renegotiated better commercial payer terms, document that clearly so the appraiser isn't stuck projecting off the older, lower rates.

A network that gets a large share of its referral volume from a small number of orthopedic surgeons or physician groups carries real risk if any one of those referral relationships weakens, whether from a competing PT practice opening nearby or a referring physician group being acquired by a health system with its own therapy arm. An appraiser who only asks about payer mix and skips referral source concentration is missing a risk factor that can matter as much as payer risk does.

Map out what share of your referral volume comes from your top five referring providers or practices, and bring that breakdown to your appraiser directly rather than assuming it will come up on its own.

A clinic director considering a partnership stake wants a number they can borrow against or plan around, which means the valuation needs to hold up under real scrutiny from their own lender or financial advisor, not just satisfy an internal formula. A buy-in priced off a valuation that doesn't account for known reimbursement changes or referral risk can leave the new partner overpaying relative to the practice's real forward earnings, which is a bad way to start a partnership.

Walk the incoming partner through how the valuation handled both reimbursement trends and referral concentration, not just the final number, so they understand what they're actually buying into.

Many outpatient PT networks sell durable medical equipment, cash-pay performance or wellness programs, or dry needling and other services that fall outside standard insurance-reimbursed physical therapy visits, and those ancillary lines often carry different margins and different payer exposure than the core visit-based business. Blending everything into one revenue number makes it harder for an appraiser to judge how much of your growth or risk is really about clinical visit volume versus a separate, discretionary line of business.

Break ancillary revenue out from core visit revenue in whatever you hand your appraiser, and be ready to explain how much of your recent growth came from each. A network whose growth is mostly ancillary, cash-pay revenue tells a different risk story than one whose growth is coming from more insurance-reimbursed visits, and the valuation should reflect that difference rather than treat every dollar the same.

A network running a handful of clinics under one practice entity, with partnership equity limited to a small group of clinic directors, is a straightforward case for either platform, and both Carta and Shareworks offer 409A ordering tied to their cap table tools, so compare current setup, pricing and turnaround. A larger network operating across many locations, or one that's taken on outside investment bringing a more complex capital structure into the group, will generally get more value from Shareworks' multi-entity administration, particularly for keeping partnership interests reconciled across a growing number of clinics.

Say a network's largest commercial payer announces a reimbursement rate reduction that takes effect three months after your annual 409A refresh date. Waiting a full year for the next scheduled refresh to reflect that cut means every option granted in the interim is priced off earnings the network won't actually be generating for most of the year. The common mistake is treating the annual refresh date as fixed regardless of what's happening in the payer environment; a reimbursement change affecting a meaningful share of revenue is a reasonable trigger to move the refresh earlier, and your attorney can help you weigh whether the change is material enough to warrant it.

Bring your appraiser these inputs before they start modeling:

• Any announced Medicare or commercial payer rate changes that affect a meaningful share of visit volume, even if they haven't reached your trailing financials yet.
• Your top referral sources and each one's share of volume, so referral concentration gets priced into the discount rate.
• Ancillary lines such as durable medical equipment, cash-pay wellness programs, and dry needling, broken out from insurance-reimbursed visits.
• Documentation of your reimbursement and referral assumptions, so a clinic director's lender or advisor can review the number.